Study of temporal distinct cellular dynamics associated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) in refractory B cell lymphoma patients
Latest Information Update: 11 Oct 2022
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 11 Oct 2022 New trial record
- 01 Sep 2022 Results published in the Nature Medicine